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Maternal inflammation at mid-gestation in pregnant rats impairs
fetal muscle growth and development at term
C. N. Cadaret,* K. A. Beede,* E. M. Merrick,* T. L. Barnes,* J. D. Loy,† and D. T. Yates*1
*Department of Animal Science and †School of Veterinary Medicine and Biomedical Sciences,
University of Nebraska-Lincoln, Lincoln 68583

INTRODUCTION

Intrauterine growth restriction (IUGR) is a leading cause of perinatal morbidity and mortality.
Low birth weight resulting from preterm birth
and/or IUGR is an underlying factor in 60-80%
of perinatal death worldwide, and is particularly common in developing countries (UNICEF,
2008). Furthermore, studies have linked IUGR
and the associated fetal malnutrition to increased
incidence of metabolic syndrome in adult life
(Barker et al., 1993; Godfrey and Barker, 2000).
The “thrifty phenotype hypothesis” developed
by David Barker (Hales et al., 1991) states that
IUGR-associated fetal malnutrition forces the fetus to spare nutrients by altering tissue-specific
metabolism in order to survive. In utero, adaptive
changes disproportionately impact skeletal muscle development, growth, and metabolism (Yates
et al., 2016). Skeletal muscle is responsible for the
majority of insulin-stimulated glucose utilization,
and adaptive restriction in muscle growth capacity
helps to spare glucose in the IUGR fetus but result
in lifelong deficits in muscle mass and metabolic homeostasis (Brown and Hay, 2016). Skeletal
muscle growth requires proliferation, differentiation, and fusion of myoblast into new muscle
fibers early in gestation and fusion with existing
fibers in the third trimester of pregnancy (Zhu et
al., 2004). This process can be impaired by inflammation from resident macrophages within skeletal
muscle. Classically-activated M1 macrophages
are pro-inflammatory but can polarize to an antiinflammatory M2 phenotype that inhibits cytokine
production and stimulates tissue repair by producing growth factors (Mantovani et al., 2004;

Kharraz et al., 2013). The acute effects of inflammatory factors on myoblast function have been
investigated in vitro (Frost et al., 1997; Guttridge
et al., 2000), and we postulate that inflammatory
stress may have similar effects on fetal myoblasts
in utero. Impaired myoblast function and the resulting decrease in muscle growth capacity affect
long-term metabolic health. Therefore, the objective of this study was to determine the effect of
sustained maternal inflammation at mid-gestation
on fetal mortality, muscle growth, and metabolic
parameters at term.
MATERIALS AND METHODS

Animals and experimental design
Animal use and care was approved by the
Institutional Animal Care and Use Committee at
the University of Nebraska-Lincoln. Animal studies were performed at the University of NebraskaLincoln Animal Science Complex, which is
accredited by the American Association for
Accreditation of Laboratory Animal Care. From
day 9 to 11 of gestation, time-mated SpragueDawley rats (Envigo, Indianapolis, IN) received
daily i.p. injections of saline (n = 6) or 100μg/
kg BW lipopolysaccharide (LPS, n = 7) from E.
coli 055:B5 (Sigma-Aldrich). Rats were weighed
daily, and maternal blood was collected and rectal temperature recorded throughout the treatment period. On day 20 of gestation, dams were
euthanized by decapitation under heavy isoflurane
anesthesia. Fetal mass and number were recorded
and maternal and fetal blood samples were collected. Fetal hind limbs were collected from three
randomly-selected fetuses per litter. For each fetus
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one hind limb was fixed in 4% PFA and the other was
snap-frozen.
Blood analysis
Maternal and fetal blood glucose concentrations
were determined at necropsy (Bayer Glucose Meter).
Plasma was isolated by centrifugation (14,000 x g, 2
min) and TNFα concentrations were determined by
Quantikine ELISA kit (R&D Systems) as previously
described (Seo et al., 2017). Inter-assay CV was less
than 10%.
Gene expression
Droplet digital PCR. RNA was extracted from fetal
hind limb (30 mg) via RNeasy Fibrous Tissue Mini Kit
(Qiagen), quantified by spectrophotometry (NanoDrop
Technologies), and reverse transcribed via QuantiTect
Reverse Transcription Kit (Qiagen). Primers for PCR
were designed and droplet digital PCR (ddPCR) was
performed with the QX200 ddPCR System (BioRad).
Each reaction contained Evagreen Supermix, 10μM of
each primer, and 1 μL of cDNA template. Droplets were
generated in a QX200 Droplet Generator with Droplet
Generator Oil, transferred to a PCR plate, sealed, and
placed in a C1000 Touch Thermal Cycler. Samples
were activated (95°C for 5 min), denatured for 40
cycles (95°C for 30 s), annealed and extended for 40
cycles (60°C for 1 min), and stabilized (4°C for 5 min
and 90°C for 5 min). Finally, droplets were read on the
QX200 Droplet Reader and results were analyzed with
QuantaSoft Software to obtain copies/μL for genes of
interest. Results for CD68, CD163, TNFR1, IL6R, insulin receptor β, and adrenergic receptors β1 and β2
were then normalized to the Ywhaz gene, which was
shown to be stable across treatment groups.
Quantitative PCR. Expression of CD68 and CD163
was also measured via qPCR by the UNL Veterinary
Diagnostic Center. RNA was extracted and cDNA was
generated as described above. Template cDNA was
standardized to 100 ng/reaction. Relative mRNA expression was determined using Power SYBR Green
PCR Master Mix kits (Applied Biosystems) and ran
on the Fast 7500 real-time PCR System. Samples were
initially denatured (10 min at 95°C), followed by 40
cycles of 95°C for 15s, and an annealing and extension phase at 60°C for 1 min. mRNA expression was
determined in triplicate from cDNA and normalized to
the concentration of the housekeeping gene β-actin the
using 2- Δ ΔCt method.
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Immunohistochemistry
Fixed fetal hind limbs were embedded in OCT
Compound (Thermo-Fisher) and 8μm cross sections
were cut and mounted on glass microscope slides.
Slides were dried at 37°C for 30 min and then thrice
washed in PBS + 0.5% Triton-X-100. Antigen retrieval was performed by boiling slides in 10 mM
citric acid for 20 minutes. Non-specific binding was
blocked with 0.5% NEN blocking buffer (PerkinElmer) at room temperature for 1 hr. Slides were
then incubated overnight at 4°C with primary antibodies diluted in PBS + 1% Bovine Serum Albumin.
Negative controls were incubated without primary
antibody. Sections were stained with rabbit antibody
against myf5 (1:100; Santa Cruz), and mouse antibodies against myoD (1:200, Dako) and myogenin (1:250,
Abcam) to identify nuclei expressing these myogenic
factors. Macrophage profiles were determined by costaining for total macrophages (CD68, 1:50; Abcam)
and M2 macrophages (CD163, 1:100; Abcam). All
nuclei were identified by counterstaining with DAPI
(1:2000, Sigma-Aldrich). Immunocomplexes were detected with Alexa Fluor 594 (1:2000; Cell Signaling)
or Alexa Fluor 488 (1:1000). Staining was visualized
on an Olympus IX73 and digital micrographs were
captured with a DP80 microscope camera (Olympus).
Images were analyzed with CellsSens Dimension
software to determine proportions of positive nuclei
within fetal skeletal muscle sections. Animal identifications and treatments were encoded to eliminate bias.
Statistical analysis
All data were analyzed by ANOVA using the GLM
procedure of SAS (SAS Institute) to determine treatment effects. Dam was the experimental unit. Skeletal
muscle mRNA concentrations from ddPCR are expressed as copies per copy of Ywhaz. Macrophage
mRNA concentrations analyzed by qPCR were normalized to β-actin and are expressed relative to the
controls. All data are expressed as means ± standard
error. Proportions of nuclei positive for myogenic factors and macrophage markers were determined from
an average of 250 and 850 positive nuclei, respectively, counted across 18 fields of view.
RESULTS

Morphometrics and blood analysis
The number of fetuses per litter did not differ
between control and LPS-treated rats, but fetal mass
was reduced (P < 0.10) in LPS fetuses (71.4±2.8 and
60.8±2.8, respectively). Maternal blood glucose was
reduced (P < 0.05) in LPS-treated rats 12 hours after
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Figure 1. Gene expression analysis for total and M2 macrophage markers in fetal hind limb as measured by qPCR (A) and ddPCR (B) * means differed (P < 0.05) between control and LPS fetuses. # means tended to differ (P < 0.10) between control and LPS fetuses.

the first daily injection but did not differ from controls otherwise (data not shown). Maternal plasma
TNFα was greater (P < 0.05) in LPS-treated rats six
hours after the first daily injection but did not differ
from controls otherwise (data not shown). Fetal blood
glucose at necropsy did not differ between treatments
(data not shown), but LPS rats tended to have greater
(P < 0.10) fetal plasma TNFα than controls (0.02±0.26
and 0.83±0.29 pg/ml, respectively).
Skeletal muscle gene expression
When measured by qPCR, CD68 mRNA expression was decreased (P < 0.05) in LPS fetal muscle but
CD163 mRNA did not differ between treatments (Figure
1). When measured by ddPCR, CD68 mRNA concentrations tended to be decreased (P < 0.10) and CD163
concentrations were decreased (P < 0.05) in LPS fetal
muscle compared to controls. TNFR1 and IL6R mRNA
tended to be reduced (P < 0.10) in LPS fetal muscle as
well (Figure 2). No differences were observed for insulin receptor or β adrenergic receptor gene expression.
Skeletal muscle immunohistochemistry
CD68-positive nuclei/μm2 tended to be decreased
(P < 0.10) in LPS fetal muscle compared to controls
but CD163-positive nuclei/μm2 were not different
(Figure 3). Likewise, the proportion of CD68-positive
nuclei–to-CD163-postive nuclei did not differ between
treatments (0.94±0.20 vs. 1.24±0.24, respectively).
MyoD-positive nuclei/μm2 were decreased (P < 0.05)
and myogenin-positive nuclei tended to be greater (P
< 0.10) in LPS fetal hind limb muscle (Figure 4), but

myf5-postive nuclei/μm2 did not differ between treatments (128.4±28.5 vs. 92.0±24.1, respectively).
DISCUSSION

In the present study, we show that reduced fetal growth
is a consequence of maternal inflammation at mid-gestation. This decrease in fetal mass near term appears to
be the result of restricted skeletal muscle growth capacity, as reduced myoD and increased myogenin in hind
limb muscle was indicative of impaired myoblast function. Fetuses from LPS-treated dams had higher concentrations of circulating TNFα near term, which indicates
that greater inflammation may be responsible for reductions in myoblast-induced fetal skeletal muscle growth.
Additionally, increased circulating cytokines were accompanied by decreases in skeletal muscle TNFR and
IL6R mRNA, which together with decreased myoD and
increased myogenin indicate a compensatory decrease in
cytokine sensitivity due to chronically high circulating
inflammatory cytokines. These findings indicate that sustained maternal inflammation at mid-gestation impairs
fetal skeletal muscle growth near term due to changes in
myoblast responsiveness to critical cytokine regulation.
Fetal mass was decreased late in gestation following sustained maternal inflammation, likely due to decreases in skeletal muscle mass. We attribute decreased
skeletal muscle growth to impaired myoblast function,
as myoD was decreased and myogenin was increased in
fetuses from LPS-treated dams. The absence of myoD
results in impaired myoblast function, as myoblasts
will continue to proliferate rather than exiting the cell
cycle and fusing with fibers (Rudnicki et al., 1993). The
combination of decreased myoD and increased myo-
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Figure 2. Gene expression analysis (ddPCR) of TNFR1 (A) and IL6R (B) in fetal hind limb after maternal inflammation. # means tended to differ (P
< 0.10) between control and LPS fetuses.

Figure 3. A. Immunostaining of markers for total (CD68) and M2
(CD163) macrophages in cross-sections of fetal hind limb muscle after maternal inflammation. A. Representative micrographs are depicted for control and LPS fetal hind limb cross sections (8μm). Sections were co-stained
for total (green) and M2 (red) macrophages and counterstained with DAPI
(blue). B. Analysis of positive total and M2 macrophages. # means differed
(P < 0.10) between control and LPS fetuses.

genin indicates a greater percentage of differentiated
myoblasts but a reduced percentage of active proliferating myoblast. This imbalance in MRF expression
represents an imbalance in the myogenic cell population and, ultimately, a deficient muscle growth capacity.
Additionally, maternal inflammation resulted in higher
concentrations of TNFα in fetal plasma, well after treatment ended. TNFα has been shown to impede differentiation and fusion of myoblasts at high concentrations
(Miller et al., 1988). High fetal inflammatory cytokines
reduced TNFR and IL6R in skeletal muscle, indicating
a reduced sensitivity to these important regulators of
skeletal muscle. Reduced sensitivity impedes the ability
of cytokines to elicit a regulatory effect on myoblasts
and causes an imbalance between proliferation and differentiation by allowing precocious differentiation.
Interestingly, increased circulating TNFα concentrations and decreased skeletal muscle cytokine sensi-

tivity was not the result of greater numbers of resident
macrophages, as mRNA and protein markers showed
decreased total macrophage populations, but no difference in M2 macrophage population in fetal hind limb
after maternal inflammation. However, these fetal macrophages are still producing greater amounts of inflammatory cytokines 10 days after maternal inflammation
has subsided. Although it is not certain whether these
inflammatory cytokines are from placental or fetal origin, the temporal spacing between induction of maternal
inflammation and fetal plasma TNFα response suggest
they are not of maternal origin. Moreover, since fetal
TNFα is greater despite decreased macrophage number,
it appears that fetal M1 macrophages have increased activity. As a compensatory action for chronic exposure
to inflammatory cytokines in LPS fetuses, the major
cytokine receptors were decreased in skeletal muscle.
Inflammatory cytokines bind to these receptors and activate the NF-ĸB signaling pathway to upregulate gene
expression of additional inflammatory cytokines, chemokines, and other inflammatory factors (Pahl, 1999).
Activation of this pathway is responsible for the inhibitory effect of cytokines on myoblast differentiation and
thus reduced sensitivity at the level of the receptor may
explain the increase in myoblast differentiation and
concurrent reduction in proliferating myoblast.
Fetal inflammation may be a direct response to
maternal inflammation or may be indirectly caused by
placental insufficiency. Maternal TNFα was acutely elevated in response to LPS treatment but did not differ
from controls at day 20 of gestation when fetuses were
collected, and in fact was not different on the second and
third days of LPS administration. Fetal circulating TNFα
was increased at term, suggesting fetal inflammation is
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Figure 4. A. Immunostaining of myoD and myogenin in fetal hind limb muscles after maternal inflammation. Representative micrographs are depicted for control and LPS fetal hind limb cross sections (8 μm). Sections were stained for myoD (red) or myogenin (green) and counterstained with DAPI
(blue). B. Analysis of myoD and myogenin positive nuclei. * means differed (P < 0.05) between control and LPS fetuses. # means differed (P < 0.10)
between control and LPS fetuses.

most likely due to placental insufficiency. Additionally,
previous studies found that inflammatory cytokines do
not typically pass the placental barrier (Aaltonen et al.,
2005), indicating that all cytokines within the fetus and
amniotic fluid are of conceptus origin.
In conclusion, maternal inflammation at mid-gestation results in decreased fetal mass due to impaired myogenesis that is still apparent at term. We demonstrate that
impaired myogenesis is due to myoblast dysfunction as
evident by decreased myoD and increased myogenin.
Moreover, myoblast dysfunction is the likely result of
increased inflammatory cytokines and the resultant decreased sensitivity to these cytokines. The inflammatory
response may be due to amplified activity of M1 macrophages, as macrophage number was actually decreased
in fetal skeletal muscle after maternal inflammation.
Together, our findings show that maternal inflammation
induces fetal adaptive responses that interrupt myoblast
regulation, causing myoblast dysfunction and impaired
skeletal muscle development and growth.
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